Salarius Gross Profit Margin from 2010 to 2024

SLRX Stock  USD 1.52  0.15  10.95%   
Salarius Pharmaceuticals Gross Profit Margin yearly trend continues to be fairly stable with very little volatility. Gross Profit Margin will likely drop to 0.59 in 2024. During the period from 2010 to 2024, Salarius Pharmaceuticals Gross Profit Margin regression line of annual values had r-squared of  0.61 and arithmetic mean of  0.60. View All Fundamentals
 
Gross Profit Margin  
First Reported
2010-12-31
Previous Quarter
0.89
Current Value
0.59
Quarterly Volatility
0.28991107
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Salarius Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Salarius Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 441.7 K, Depreciation And Amortization of 9.55 or Interest Expense of 281.6 K, as well as many indicators such as Price To Sales Ratio of 97.37, Dividend Yield of 0.0011 or PTB Ratio of 3.05. Salarius financial statements analysis is a perfect complement when working with Salarius Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Salarius Pharmaceuticals Correlation against competitors.
For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.

Latest Salarius Pharmaceuticals' Gross Profit Margin Growth Pattern

Below is the plot of the Gross Profit Margin of Salarius Pharmaceuticals over the last few years. It is Salarius Pharmaceuticals' Gross Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Salarius Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Gross Profit Margin10 Years Trend
Slightly volatile
   Gross Profit Margin   
       Timeline  

Salarius Gross Profit Margin Regression Statistics

Arithmetic Mean0.60
Geometric Mean0.54
Coefficient Of Variation48.57
Mean Deviation0.25
Median0.49
Standard Deviation0.29
Sample Variance0.08
Range0.6546
R-Value0.78
Mean Square Error0.03
R-Squared0.61
Significance0.0006
Slope0.05
Total Sum of Squares1.18

Salarius Gross Profit Margin History

2024 0.59
2023 0.89
2021 0.99
2019 1.0
2018 0.49
2017 0.6

About Salarius Pharmaceuticals Financial Statements

Salarius Pharmaceuticals investors use historical fundamental indicators, such as Salarius Pharmaceuticals' Gross Profit Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Salarius Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Gross Profit Margin 0.89  0.59 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Salarius Stock Analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.